NO20033166D0 - Prodrugs for eksitasjon av aminosyrer - Google Patents

Prodrugs for eksitasjon av aminosyrer

Info

Publication number
NO20033166D0
NO20033166D0 NO20033166A NO20033166A NO20033166D0 NO 20033166 D0 NO20033166 D0 NO 20033166D0 NO 20033166 A NO20033166 A NO 20033166A NO 20033166 A NO20033166 A NO 20033166A NO 20033166 D0 NO20033166 D0 NO 20033166D0
Authority
NO
Norway
Prior art keywords
prodrugs
excitation
amino acids
acids
amino
Prior art date
Application number
NO20033166A
Other languages
English (en)
Other versions
NO20033166L (no
Inventor
David Scott Coffey
James Allen Monn
Steven Wayne Pedersen
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01500263A external-priority patent/EP1310480A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20033166D0 publication Critical patent/NO20033166D0/no
Publication of NO20033166L publication Critical patent/NO20033166L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
NO20033166A 2001-01-11 2003-07-10 Prodrugs av eksitatoriske aminosyrer NO20033166L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01500007 2001-01-11
EP01500206 2001-08-02
US32978601P 2001-10-16 2001-10-16
EP01500263A EP1310480A1 (en) 2001-11-07 2001-11-07 Prodrugs of excitatory amino acids
PCT/US2001/045866 WO2002055481A1 (en) 2001-01-11 2001-12-21 Prodrugs of excitatory amino acids

Publications (2)

Publication Number Publication Date
NO20033166D0 true NO20033166D0 (no) 2003-07-10
NO20033166L NO20033166L (no) 2003-09-09

Family

ID=27440162

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033166A NO20033166L (no) 2001-01-11 2003-07-10 Prodrugs av eksitatoriske aminosyrer

Country Status (24)

Country Link
US (1) US7256217B2 (no)
EP (1) EP1368304B1 (no)
JP (1) JP4064237B2 (no)
KR (1) KR20030090622A (no)
CN (1) CN1267407C (no)
AR (1) AR036007A1 (no)
AT (1) ATE356111T1 (no)
AU (1) AU2002228737B2 (no)
BR (1) BR0116770A (no)
CA (1) CA2433667C (no)
CZ (1) CZ303490B6 (no)
DE (1) DE60127182T2 (no)
DZ (1) DZ3461A1 (no)
ES (1) ES2282315T3 (no)
HU (1) HUP0400620A3 (no)
IL (1) IL156364A0 (no)
MX (1) MXPA03006186A (no)
NO (1) NO20033166L (no)
NZ (1) NZ526050A (no)
PE (1) PE20020829A1 (no)
PL (1) PL208413B1 (no)
SK (1) SK287934B6 (no)
SV (1) SV2003000836A (no)
WO (1) WO2002055481A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014979B1 (ru) * 2002-06-11 2011-04-29 Эли Лилли Энд Компани Пролекарства возбуждающих аминокислот
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
CA2836485C (en) 2011-06-17 2016-12-13 Eli Lilly And Company Bicyclo (3.1.0) hexane- 2,6 -dicarboxylic acid derivatives as mglu2 receptor agonist
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
MX2020010937A (es) 2018-04-17 2020-11-06 Bayer Ag Metodo para la preparacion de esteres de aminoacidos n-acilados con funciones de grupo protector cetona labil al acido.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
WO1996004901A1 (en) * 1994-08-12 1996-02-22 Eli Lilly And Company Composition and method for treating anxiety
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
IL118727A (en) * 1995-06-29 2003-01-12 Lilly Co Eli (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ATE236118T1 (de) 1998-01-28 2003-04-15 Taisho Pharmaceutical Co Ltd Fluorhaltige aminosäurederivate
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
WO2002055485A1 (en) 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1423411A2 (en) 2001-07-09 2004-06-02 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
US20050009912A1 (en) 2001-12-21 2005-01-13 Bueno Melendo Ana Belen Prodrugs of excitatory amino acids

Also Published As

Publication number Publication date
CN1267407C (zh) 2006-08-02
BR0116770A (pt) 2003-12-23
ES2282315T3 (es) 2007-10-16
DE60127182D1 (de) 2007-04-19
DZ3461A1 (fr) 2002-07-18
PL208413B1 (pl) 2011-04-29
JP2004524292A (ja) 2004-08-12
CN1486298A (zh) 2004-03-31
US7256217B2 (en) 2007-08-14
CZ303490B6 (cs) 2012-10-17
IL156364A0 (en) 2004-01-04
PE20020829A1 (es) 2002-09-21
US20040121962A1 (en) 2004-06-24
SK8262003A3 (en) 2004-01-08
JP4064237B2 (ja) 2008-03-19
KR20030090622A (ko) 2003-11-28
SK287934B6 (sk) 2012-05-03
DE60127182T2 (de) 2007-11-22
CZ20031916A3 (en) 2004-03-17
NO20033166L (no) 2003-09-09
WO2002055481A8 (en) 2003-10-02
AU2002228737B2 (en) 2007-01-04
HUP0400620A2 (hu) 2004-12-28
ATE356111T1 (de) 2007-03-15
CA2433667C (en) 2011-06-14
MXPA03006186A (es) 2004-02-13
SV2003000836A (es) 2003-01-13
NZ526050A (en) 2005-03-24
PL361669A1 (en) 2004-10-04
EP1368304B1 (en) 2007-03-07
AR036007A1 (es) 2004-08-04
EP1368304A1 (en) 2003-12-10
WO2002055481A1 (en) 2002-07-18
HUP0400620A3 (en) 2012-09-28
CA2433667A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
CY2012006I1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer
NO20054958D0 (no) Substitulerte aminokarboksylsyrer
NO20040084L (no) Peptid-baserte forbindelser
DE60234125D1 (de) E inhibitoren
ATE517887T1 (de) Neue 2-pyridincarbonsäureamidderivate
DE60236135D1 (de) Verfahren zur Herstellung von N-langkettig acylsubstituierten neutralen Aminosäuren
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
DK1517915T3 (da) Promedikamenter af excitatoriske aminosyrer
PT1370553E (pt) Inibidores de rhoquinase
DE60144083D1 (de) Verfahren zur Herstellung von basischen Aminosäuren
NO20043102L (no) Fjerning av sure gasser
DE50104794D1 (de) Substituierte anthranilsäuren
NO20040292L (no) Fremgangsmate for fremstilling av 4-aminodifenylamin
DK1892239T3 (da) Inhibitorer af cytosol-phospholipase A2
DE60217089D1 (de) Lipidsenkende biphenylcarbonsäureamide
FR2825717B1 (fr) Preparation stereoselective de l-acides amines cycliques
NO20023445L (no) Fremgangsmåte for fremstilling av peptider
NO20033166D0 (no) Prodrugs for eksitasjon av aminosyrer
FI20012446A0 (fi) Menetelmä kartongin jälkikäsittelemiseksi
NO20033356L (no) Fremgangsmåte for fremstilling av DTPA-monoamider
DE10290206D2 (de) Verfahren zur Regelung der Fahrstabilität
DK1399577T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer
DE50115802D1 (de) Dafür

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application